Corwin EJ. Buku saku patofisiologi corwin. Jakarta: Penerbit Buku Kedokteran EGC, 2009. H. 296-9.

Penyakit Hipertirodisme

Penyakit Graves, penyakit tersering hipertirodisme, adalah gangguan autoimun yang biasanya ditandai dengan produksi autoantibodi yang mirip kerja TSH pada kelenjar tiroid. Autoantibodi IgG ini, yang disebut thyroid stimulating immunoglobulin, menstimulasi produksi TH, namun tidak dihambat oleh kadar TH yang meningkat. Penyebab penyakit Graves tidak diketahui; akan tetapi, tampak terdapat predisposisi genetic pada penyakit autoimun. Wanita yang berusia 20-an dan 30-an paling sering terdiagnosis penyakit ini walaupun penyakit ini mulai terjaddi selama usia belasan tahun.

Goiter nodular adalah peningkatan ukuran kelenjar tiroid akibat peningkatan kebutuhan akan hormon tiroid. Peningkatan kebutuhan akan hormon tiroid terjadi selama periode pertumbuhan atau kebutuhan metabolik yang tinggi misalnya kebutuhan metabolic yang tinggi misalnya pubertas atau kehamilan. Dalam kasus ini, peningkatan TH disebabkan oleh aktivitas hipotalamus yang didorong oleh proses metabolisme sehingga disertai oleh peningkatan TRH dan TSH. Apabila kebutuhan akan hormone tiroid berkurang, ukuran kelenjar tiroid biasanya kembali ke ukuran sebelumnya. Kadang-kadang terjadi perubahan yang irreversible dan kelenjar tidak mengalami regresi. Tiroid yang membesar dapat terus memproduksi TH dalam jumlah berlebihan. Apabila individu tetap mengalami hipertiroid, keadaan ini disebut goiter nodular toksik.

Adenoma hipofisis pada sel-sel penghasil TSH atau penyakit hipotalamus jarang terjadi.

Gambaran klinis

Peningkatan frekuensi jantung. Peningkatan tonus otot, tremor, iritabilitas, peningkatan sensitivitas terhadap katekolamin. Peningkatan laju metabolisme basal dan produksi panas, intoleransi terhadap panas, keringat

berlebihan. Penurunan berat badan, peningkatan rasa lapar. Melotot. Dapat terjadi eksoftalmus (penonjolan bola mata). Peningkatan frekuensi buang air besar. Gondok (biasanya), yaitu peningkatan ukuran kelenjar tiroid. Perubahan kulit dan kondisi rambut dapat terjadi.

Korelasi

Diagnosis kerja

Penyakit

Diagnosis banding

Struma multinodular toksik

Nodul tunggal (single hot nodule) ?

Tiroiditis

Adenoma toksik

Karsnioma toksik

Lain-lainnya

Etiologi

Penyakit Graves sekarang ini dipandang sebagai penyakit autoimun yang penyebabnya tidak diketahui. Terdapat predisposisi familial kuat pada sekitar 15% pasien Graves mempunyai keluarga dekat dengan kelainan sama dan kira-kira 50% keluarga pasien dengan penyakit Graves mempunyai autoantibody tiroid yang beredar di darah. Wanita terkena kira-kira 5 kali lebih banyak daripada pria. Penyakit ini dapat terjadi pada segala umur, dengan insiden puncak pada kelompok umur 20-40 tahun. Fotokopi

Patofisiologi

Penatalaksanaan

Komplikasi

Prognosis

Graves' disease is a thyroid-specific autoimmune disorder in which the body makes antibodies to the thyroid-stimulating hormone receptor (TSHR), leading to hyperthyroidism, or an abnormally strong release of hormones from the thyroid gland. Normally, the release of thyroid hormones is mediated by thyroid-stimulating hormone (TSH), a hormone secreted by the pituitary gland that binds to TSHR to stimulate the thyroid to release thyroid hormones. This normal cycle is self-regulating: the hormones secreted by the thyroid keep more TSH from being produced (Janeway, 2001). The autoantibodies produced in Graves' disease are not subject to negative feedback, so they continue to be produced and bind to TSHR even when thyroid hormone levels rise too high. These antibodies act as agonists, stimulating more hormones to be released and thus leading to hyperthyroidism.

Clinical Symptoms of Graves' Disease:

Patients with Graves' disease can exhibit a variety of symptoms related to hyperthyroidism, including diffuse goiter (enlarged thyroid gland), rapid pulse, weight loss and trembling. In addition, some patients with Graves' disease exhibit symptoms unique to this form of hyperthyroidism, including ophthalmopathy (bulging eyes) and rarely, pretibial myxedema (swelling of shins) (ATA, 2003). The symptoms of Graves' disease stem partly from hyperthyroidism and partly as a consequence of autoimmunity.

 

Figure 2: Patient with a large goiter, prominent on the left side of the neck.Figure taken with permission from www.thyroidimaging.com

 

Figure 3: Patient with opthalmopathy. Figure taken pending permission from www.thyroidmanager.org

 

Figure 4: Patient with pretibial myxedema.Figure taken pending permission from www.thyroidmanager.org

 

Risk Factors:

Several factors can influence a person's susceptibility to Graves' disease, although the mechanism of initiation remains unknown. Females are much more likely to contract the disease than males, with the highest-risk ages for either sex being between 40 and 60 years (Weetman, 2000). Thus, hormone levels are probably important in the initiation of the disease. White and Asian populations are at higher risk than black populations. Often, the onset of Graves' disease is preceded by a traumatic event, implicating that stress may play a role in initiation. Smoking is also a significant risk factor; it is most strongly associated with the development and persistence of ophthalmopathy in Graves' disease patients, even after treatment (Bartalena et al., 1998).

Genetic factors are important, but not determinative, for predisposition to Graves' disease. Twin studies show a 20 percent concordance rate between monozygotic twins

with the disease and lower rates among dizygotic twins and HLA-identical siblings. Several HLA alleles have been shown to predispose certain groups of people to the disease, with regional and racial variation (Weetman, 2000). Among the alleles implicated among British Caucasians are HLA class II alleles DRB1-0304, DQB1-02, and DQA1-0501 (Heward et al., 1998). The association of HLA alleles with susceptibility to Graves' disease is typical of an autoimmune disorder. Allelic affinity for different peptides directly influences which self-peptides will be produced and how likely it is that they will be recognized by T cells.

Genetic analysis has shown that polymorphisms in the cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene are associated with Graves' disease (Weetman, 2000). CTLA-4 is a receptor expressed on activated T cells that inhibits T cell proliferation by binding to the costimulatory B7 molecule and preventing further activation. The polymorphisms linked to Graves' disease may correspond with lessened effectiveness of this inhibitory receptor (Kouki et al., 2000). CTLA-4 has also been linked to other organ-specific autoimmune diseases, indicating that it may play a general role in autoimmunity.

Another gene that Pani, et al. (2002) have linked to Graves' disease is the vitamin D-binding protein (DBP) gene. Graves' disease patients have much less vitamin D in their bloodstream than healthy individuals. Pani, et al. found that in a study of several families, a polymorphism of the DBP gene was associated with susceptibility to Graves' disease but not Hashimoto's thyroiditis, a hypothyroid illness. The mechanism whereby DBP could affect autoimmunity is unknown, but such a relationship indicates that vitamin D regulation might be important in Graves' disease.

 

Immune System Involvement:

Many of the symptoms of Graves' disease are directly related to its cause: organ-specific autoimmunity. For example, the goiter that is typical of Graves' disease is caused by swelling of the thyroid due to inflammation and lymphocyte infiltration. Lymphocytes within the thyroid contribute to further autoimmune responses, and the thyroid cells themselves interact with the immune system to exacerbate the symptoms of hyperthyroidism. These thyrocytes express proteins they normally would not, including HLA class II molecules, CD40, adhesion molecules such as CD54, and cytokines such as TNF-, IFN-, IL-1 and IL-6. Germinal centers can form within the thyroid tissue of affected individuals, exacerbating the autoimmune response and causing further inflammation (Weetman, 2000). Likewise, the ophthalmopathy associated with Graves' disease is due to retroorbital swelling from lymphocyte and macrophage infiltration. Orbital fibroblasts are known to secrete TSHR, so

presumably the recognition of TSHR antigen leads to this inflammatory response. However, the mechanism for this specific response to the extraocular muscles is puzzling, since other antigen-producing preadipocytes throughout the body remain untargeted (Weetman, 2000).

 

Figure 5: Proposed mechanism of Graves' disease pathogenesis. Figure taken pending permission from Ginsberg, 2003.

One of the hallmarks of Graves' disease is the prevalence of a Th2 response rather than a Th1 or CD8 T cell response. The Th2 dominance is achieved through "abnormal" T cell-dependent B-cell activation, which leads to the release of cytokines specific for a Th2 response, particularly IL-10 (Itoh et al., 1998). Suppression of CD8 cells by this Th2 response may accentuate the symptoms of Graves' disease. CD8-expressing cells can work to counteract Th2 dominance; in fact, studies have shown that secretion of sCD8 is particularly marked during the active phase of Graves' disease (Watanabe, 1997). However, in hyperthyroid individuals, levels of CD8-expressing cells are lower than in euthyroid individuals, indicating that prevalence of the Th2 response is associated with more pronounced symptoms (Bossowski et al., 2003). A study by Aust, et al. (1996) suggests that NK cells, as well as CD8 cells, may help prevent B cell infiltration of the thyroid. In this study, some patients with high numbers of NK cells in their thyroid had lower levels of B cells than those with fewer NK cells.

Once they collect in the thyroid of Graves' disease patients, autoimmune lymphocytes express different molecules than their peripheral blood counterparts. Higher levels of CD8 are expressed and secreted by lymphocytes within the thyroid of affected individuals than in peripheral blood mononuclear cells (Itoh et al., 2002; Uchimura et al., 2002). The expression of cytokines changes as well. A study by Aust, et al. (2002) compared the expression of CXCR3 and CCR5 in peripheral and thyroid-derived lymphocytes in Graves' disease patients. They found that thyroid-derived lymphocytes expressed much more CCR5 and CXCR3 than lymphocytes from the peripheral blood of the same individuals. CXCR3 and CCR5 may be involved in recruiting more lymphocytes to the thyroid.

Apoptosis is abnormally regulated during the course of Graves' disease, and thyrocytes in affected individuals undergo lower-than-normal levels of apoptosis. These thyrocytes express subnormal levels of Fas and high levels of Bcl-2 (an anti-apoptotic protein). Conversely, thyroid-infiltrating lymphocytes (TILs) in Graves' disease express high levels of both Fas and FasL and low levels of Bcl-2 ; TILs in Graves' disease patients thus exhibit high levels of apoptosis (Salmaso et al., 2002). This abnormal apoptotic regulation suppresses the effects of infiltrating lymphocytes while allowing thyroid cells to persist longer than normal. These results contribute to hyperthyroidism.

Current Treatments:

Rather than targeting the immune response that causes Graves' disease, current Graves' disease treatments focus on restoring normal thyroid function by compensating for the hyperthyroidism of the disease. This is done either by radioiodine, antithyroid drugs, or surgery. The prevalence of each of these treatments varies regionally; each can be effective but also has potential side effects.

Radioiodine is the most common treatment for Graves' disease in North America. Patients ingest capsules or solutions of radioactive iodine, which is absorbed by the thyroid and causes localized death of thyroid tissue, typically counteracting hyperthyroidism within 6-18 weeks. The risk due to radioactivity is low--treatment has not been associated with "birth defects, infertility or overall cancer incidence" (Ginsberg, 2003). However, patients who are pregnant should not undergo radioiodine treatment because it could lead to hypothyroidism in their infants. A potential side effect of this and other treatments is the development of hypothyroidism in the patient as well. Conversely, some patients require more than one round of radioiodine to correct their hyperthyroidism.

Antithyroid drugs act by interfering with thyroid hormone synthesis. In patients with pronounced hyperthyroidism, treatment with antithyroid drugs may not be enough to send the disease into permanent remission, but 30 to 40 percent of patients treated with them undergo remissions of ten years or more (Weetman, 2000). For patients with a large goiter, thyroidectomy is often preferred because of its high efficacy in restoring euthyroidism, although hypothyroidism can result when most of the thyroid is removed. Hypothyroidism must be treated with supplementary thyroid hormones.